Tristel (TSTL) H1 2025 earnings summary

Executive summary

• Revenue increased 8% year-over-year to £22.6m, with adjusted profit before tax up 19% to £4.9m and adjusted EBITDA up 14% to £6.3m, maintaining strong cash generation and no debt.

• Medical device decontamination accounted for 87% of H1 sales, with significant growth potential in the US and ongoing geographic expansion and product innovation.

• Gross margin improved to 82% (from 81%), and interim dividend increased to 5.68p per share, reflecting a progressive dividend policy.

• CEO transition completed in September 2024, with Matt Sassone bringing significant US healthcare experience.

• Business remains profitable, cash generative, and on track to meet current financial goals.

Financial highlights

• Revenue: £22.6m (up 8% year-over-year); UK: £8.8m (up 7%), Overseas: £13.8m (up 9%).

• Adjusted profit before tax: £4.9m (up 19%); Adjusted EBITDA: £6.3m (up 14%); EBITDA margin: 28%.

• Adjusted EPS: 8.17p (down from 8.68p); Reported EPS: 5.72p (down from 6.50p), impacted by higher tax rate.

• Cash and deposits at £11.7m, with no debt.

• Interim dividend increased to 5.68p per share; £3.9m in dividends paid during the period.

Outlook and guidance

• Confident in returning to double-digit revenue growth, with all current growth challenges considered fixable.

• Management targets 10-15% CAGR revenue growth over three years to June 2025, driven by international expansion and product innovation.

• Expecting FDA clearance for ophthalmology product by summer 2025, with preparations for rapid commercial launch.

• Focus on international expansion, especially in Spain, India, Austria, and the USA.

• Confident in meeting current financial goals and unlocking high-margin, long-term growth.